Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
2010 · New England Journal of Medicine · 15K citations
https://doi.org/10.1056/nejmoa1003466
M
Michael Yellin
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
187
Papers
26.7K
Citations
42
h-index
79
i10-index
Michael Yellin is an academic researcher from Celldex Therapeutics (United States). The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & Immunotherapy and Immune Responses & CAR-T cell therapy research. The author has an h-index of 42, co-authored 159 publications.
ORCID: 0000-0002-1164-7614Papers by this author
worksIdentification of a novel surface protein on activated CD4+ T cells that induces contact-dependent B cell differentiation (help).
1992 · The Journal of Experimental Medicine · 353 citations
https://doi.org/10.1084/jem.175.4.1091
Molecular interactions mediating T-B lymphocyte collaboration in human lymphoid follicles. Roles of T cell-B-cell-activating molecule (5c8 antigen) and CD40 in contact-dependent help
1992 · The Journal of Immunology · 194 citations
https://doi.org/10.4049/jimmunol.149.12.3817
CD40L-CD40 interactions regulate endothelial cell surface tissue factor and thrombomodulin expression
1998 · Journal of Leukocyte Biology · 157 citations
https://doi.org/10.1002/jlb.63.3.373
Immunohistologic analysis of renal CD40 and CD40L expression in lupus nephritis and other glomerulonephritides
1997 · Arthritis & Rheumatism · 156 citations
https://doi.org/10.1002/art.1780400117
T lymphocyte T cell-B cell-activating molecule/CD40-L molecules induce normal B cells or chronic lymphocytic leukemia B cells to express CD80 (B7/BB-1) and enhance their costimulatory activity.
1994 · The Journal of Immunology · 143 citations
https://doi.org/10.4049/jimmunol.153.2.666
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat